Project Grant R03DA063752
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $397,829 Project Grant to Callentis Consulting Group LLC, a woman-owned small business in Austin, Texas. The grant, awarded on May 1, 2025, supports the development of an artificial intelligence (AI) platform to discover new therapeutics for substance use disorders. The key products and services to be delivered include: 1) Curated training datasets and machine learning...
- This $325,734 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund the development, evaluation, and dissemination of "STATWISEAI" - an AI-powered educational tool to enhance methodological rigor in analyzing complex, large-scale datasets for biomedical and behavioral research. The key products and services to be delivered through this 3-year award (9/15/2025 - 8/31/2028) include: 1)...
- This $1,483,186 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2025. The grant recipient, Verisim Life, Inc., is using the funding to develop an AI-driven drug discovery platform to accelerate the development of novel therapeutic agents for stimulant use disorder (STUD), a critical unmet medical need. During the Phase I effort, Verisim Life integrated...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $608,652 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Scripps Research Institute. The purpose of this 5-year award, with a start date of September 1, 2025, is to conduct data mining and functional validation of the Systematic Characterization of Retroviral Conditions for Health (SCORCH) datasets. The research aims to elucidate the key pathogenic...
- The National Institute of Justice (NIJ) awarded a $2,000,000 Cooperative Agreement under the Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) to The Fredric Rieders Family Renaissance Foundation. The award, effective January 1, 2025 through December 31, 2027, will establish the Novel Psychoactive Substance Discovery, Education, and Reporting Institute (NPS DISCERN). The project aims to rapidly identify emerging drugs and changes in drug markets by characterizing...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $407,382 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Texas at Austin (UT Austin). The grant, titled "REPRESENTATIONAL GEOMETRY: EVALUATING BRAIN-COMPUTATIONAL MODELS WITH NEURAL ACTIVITY DATA", will fund a collaboration between theorists and experimentalists to develop rigorous methods for evaluating and comparing complex...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $558,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Massachusetts Institute of Technology (MIT) for the project "Integration and Validation of Single-Cell Neuronal and Immune Molecular Responses in SUD and HIV". The project aims to uncover the genetic and molecular mechanisms driving the interactions between HIV, neuropsychiatric, and...
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $306,872 Project Grant to Biomotivate LLC to develop and evaluate the PEACE Platform, a novel solution that leverages personalized audiovisual content and machine learning algorithms to help individuals with opioid use disorders (OUDs) build their capacity to manage negative emotions and stressors. The research design involves integrating generative AI, predictive...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $283,968 Project Grant to the Regents of the University of Michigan to build an "AI Forest" to study the social and environmental factors underlying complex behavioral traits in wild white-faced capuchin monkeys in Costa Rica. The project, which runs from March 2025 to February 2027, will leverage new technologies to probe brain-behavior relationships and assess...
The National Institute on Drug Abuse (NIDA) awarded a $164,000 Project Grant to The Trustees of Princeton University for the development of a "Chemical AI and Data Science Platform for the Identification and Discovery of Novel Psychoactive Substances." The 2-year project, running from August 2025 to July 2027, aims to create a comprehensive database of known novel psychoactive substances (NPS) and leverage artificial intelligence (AI) tools to predict the structure and mass spectrometry properties of unknown NPS that may emerge on the illicit market. This work under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) is intended to assist toxicology laboratories in detecting both known and unknown NPS, addressing the challenges posed by the rapid proliferation of diverse NPS. The project will leverage Princeton University's expertise in areas such as quantum computing, AI, and advanced analytical techniques to develop innovative solutions for this pressing public health concern.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $164.0k | 8/4/25 |